Article

<i>CDK12</i> Loss Promotes Prostate Cancer Development While Exposing Vulnerabilities to Paralog-Based Synthetic Lethality

2024-03-21

Abstract excerpt

<h4>SUMMARY</h4> Biallelic loss of cyclin-dependent kinase 12 ( CDK12 ) defines a unique molecular subtype of metastatic castration-resistant prostate cancer (mCRPC). It remains unclear, however, whether CDK12 loss per se is sufficient to drive prostate cancer development—either alone, or in the context of other genetic alterations—and whether CDK12 -mutant tumors exhibit sensitivity to specific pharmacothera...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 9eb46dff-1e73-54de-a9fc-fc54c89e44d9
DOI: 10.1101/2024.03.20.585990

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

<i>CDK12</i> Loss Promotes Prostate Cancer Development While Exposing Vulnerabilities to Paralog-Based Synthetic LethalityDOI 10.1101/2024.03.20.585990Read

CDK12 loss drives prostate cancer progression, transcription-replication conflicts, and synthetic lethality with paralog CDK13Semantic proximity Read

CRISPR screening identifies CDK12 as a conservative vulnerability of prostate cancerSemantic proximity Read

Synthetic Lethal Targeting of CDK12-Deficient Prostate Cancer with PARP Inhibitors.Semantic proximity Read

Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer.Semantic proximity Read

Biobank of genetically defined murine prostate cancer tumoroids uncovers oncogenic pathways and drug vulnerabilities driven by PTEN-lossSemantic proximity Read

Compromised CDK12 activity causes dependency on the non-essential spliceosome componentsSemantic proximity Read

ProMPt: A modular preclinical platform for functional modelling of prostate cancer heterogeneity and therapeutic vulnerabilitiesSemantic proximity Read

CRISPR/Cas9 model of prostate cancer identifies Kmt2c deficiency as a metastatic driver by Odam/Cabs1 gene cluster expressionSemantic proximity Read

Molecular consequences of acute versus chronic CDK12 loss in prostate carcinoma nominates distinct therapeutic strategiesSemantic proximity Read

MYBL2 drives prostate cancer plasticity and identifies CDK2 as a therapeutic vulnerability in RB1-loss and neuroendocrine prostate cancerSemantic proximity Read

Combined <i>MYC</i> Activation and <i>Pten</i> Loss Are Sufficient to Create Genomic Instability and Lethal Metastatic Prostate CancerSemantic proximity Read

Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced Prostate Cancer.Semantic proximity Read